Alnylam Pharmaceuticals Stock News

Full results from the pivotal ILLUMINATE-A study support the efficacy of the drug in treating PH1, with meaningful improvements in urinary oxalate levels in the

The number of deaths from the coronavirus that causes COVID-19 rose above 400,000 on Monday, as anti-racism protests swept the U.S. and much of the rest of...

Alnylam (ALNY) reports positive phase III results from the ILLUMINATE-A study on lumasiran.

REGN has gone from doormat to leader in short order. There have been multiple drivers of this, one of which is discussed below: immuno-oncology (IO). Behind the

Alnylam has revealed the data that forms the basis of its filings for its latest rare disease drug contender, lumasiran, but shares dipped after an analyst suggested it could be outperformed by a con

Alnylam Pharmaceuticals (ALNY) has announced positive Phase 3 results from the ILLUMINATE-A study of lumasiran for the treatment of primary hyperoxaluria type 1 (PH1).PH1 is an ultra-rare orphan disea

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive Phase 3 results from the ILLUMINATE-A study of lumasiran, an investigational RNAi therapeu

Coronavirus (Covid-19) Vaccine Latest Update: US has selected five companies as the most likely candidates to produce a vaccine; Moderna is looking to start final phase of trials as early as July.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive Phase 3 results from the ILLUMINATE-A st

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced findings from two new interim analyses of data from the Phase 3 H

Dr. Anthony Fauci, the head of the National Institute for Allergy and Infectious Diseases, said in a Friday interview on D.C.-based radio station WTOP he is concerned that the widespread protests tak

‘We will have coronavirus in the fall: I am convinced of that,’ Fauci said two months ago.